The quarter cleared a relatively modest market hurdle. Published estimates called for roughly $5.08 of diluted EPS and $240.7 million of revenue; HCI delivered $5.60 and $246.7 million, or approximately 10% and 2.5% above expectations, respectively.
| Metric | Q2 2026 | Q2 2025 / expectation | Read |
|---|---|---|---|
| Diluted EPS | $5.60 (Consolidated Statements of Income) | $5.18 prior year; ~$5.08 consensus | Beat by roughly 10% |
| Total revenue | $246.7 million (Consolidated Statements of Income) | $221.9 million prior year; ~$240.7 million consensus | Up 11%; modest beat |
| Gross premiums earned | $320.8 million (Selected Financial Metrics) | $302.6 million prior year | Up 6% |
| Gross loss ratio | 22.2% (Selected Financial Metrics) | 21.3% prior year | 90-basis-point deterioration |
| Net income after noncontrolling interests | $73.8 million (Consolidated Statements of Income) | $66.2 million prior year | Up 12% |
| Share repurchases | $57.0 million in Q2; $80.0 million completed July 17, 2026 (Share Repurchase) | $80.0 million authorization | Program fully used |
The earnings beat came from more than premium growth alone. Gross premiums earned increased 6%, while lower catastrophe-reinsurance costs helped premiums ceded fall slightly to $101.8 million (Revenue). Net investment income rose to $18.9 million as invested assets expanded, and Exzeo-related other revenue doubled to $5.1 million (Revenue). Those factors helped pre-tax income rise 18% to $111.0 million despite higher claims and operating costs (Consolidated Statements of Income).
Underlying underwriting was good, but not cleaner than last year. The gross loss ratio moved up to 22.2% from 21.3%, and general and administrative personnel expense increased 20% to $23.9 million as HCI added staff and incurred higher compensation costs (Selected Financial Metrics; Consolidated Statements of Income). The result is still strong in absolute terms, but the market's positive read rests partly on reinsurance savings, investment income, and non-insurance revenue rather than improving claims performance.
Capital deployment was completed earlier than the original deadline, but it is not a new surprise. HCI repurchased 504,330 shares for $80.0 million and completed the authorization on July 17, 2026, reducing the share count and supporting per-share results (Share Repurchase; Selected Financial Metrics). Because the program had already been announced and was substantially deployed before the filing, this is confirmation rather than a fresh catalyst.
Net: a clear positive surprise versus consensus, with the main caveat in underwriting quality. Six-month diluted EPS reached $11.05 versus $10.57 a year earlier, while gross premiums earned rose 7% to $647.0 million (Six Months Ended June 30, 2026 Results; Consolidated Statements of Income). No new forward earnings guidance was provided, so the filing improves the current earnings picture without changing an explicit full-year outlook.
Read the original 8-K on SEC EDGAR ↗